BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32055023)

  • 1. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
    Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
    Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity.
    Gonnermann D; Oberg HH; Lettau M; Peipp M; Bauerschlag D; Sebens S; Kabelitz D; Wesch D
    Front Immunol; 2020; 11():1328. PubMed ID: 32695112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.
    Kimura H; Yamamoto H; Harada T; Fumoto K; Osugi Y; Sada R; Maehara N; Hikita H; Mori S; Eguchi H; Ikawa M; Takehara T; Kikuchi A
    Clin Cancer Res; 2019 Mar; 25(6):1936-1947. PubMed ID: 30610103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of galectin-3 in pancreatic ductal adenocarcinoma.
    Gaida MM; Bach ST; Günther F; Baseras B; Tschaharganeh DF; Welsch T; Felix K; Bergmann F; Hänsch GM; Wente MN
    Pathol Oncol Res; 2012 Apr; 18(2):299-307. PubMed ID: 21910036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
    Li Q; Wang H; Zogopoulos G; Shao Q; Dong K; Lv F; Nwilati K; Gui XY; Cuggia A; Liu JL; Gao ZH
    Oncotarget; 2016 Nov; 7(47):77838-77853. PubMed ID: 27788482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression and serum levels in pancreatic cancer.
    Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
    World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
    Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
    Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice.
    Quilbe A; Mustapha R; Duchêne B; Kumar A; Werkmeister E; Leteurtre E; Moralès O; Jonckheere N; Van Seuningen I; Delhem N
    Front Immunol; 2023; 14():1267279. PubMed ID: 38098486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
    Liberati D; Marzinotto I; Brigatti C; Dugnani E; Pasquale V; Reni M; Balzano G; Falconi M; Piemonti L; Lampasona V
    Cancer Biomark; 2018; 22(2):351-357. PubMed ID: 29660901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma.
    Gao Y; Wang M; Guo X; Hu J; Chen TM; Finn SMB; Lacy J; Kunstman JW; Cha CH; Bellin MD; Robert ME; Desir GV; Gorelick FS
    PLoS One; 2021; 16(9):e0250539. PubMed ID: 34587190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CD74 on the prognosis of patients with resectable pancreatic cancer.
    Zhang JF; Hua R; Liu DJ; Liu W; Huo YM; Sun YW
    Hepatobiliary Pancreat Dis Int; 2014 Feb; 13(1):81-6. PubMed ID: 24463084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.